Non small-cell lung cancer
Higher radon exposure linked to increased lung cancer risk in UK-first study
Serial imaging-based deep learning effectively predicts survival in immunotherapy-treated NSCLC
Registry data support safety of stereotactic radiotherapy with newer cancer treatments
Preoperative ctDNA test shows promise in predicting early-stage lung adenocarcinoma outcomes
Perioperative pembrolizumab and overall survival in early-stage NSCLC
Dr John Conibear on the evolution of durvalumab in NSCLC care
Three NSCLC indications included in positive CHMP opinion for tislelizumab
Adagrasib approved in the UK for NSCLC after earlier EU rejection
Circulating tumour DNA biopsy helps identify NSCLC patients suitable for radiotherapy
Alectinib shows promise in early-stage ALK-positive non-small cell lung cancer
Specific enzyme tissue expression close to tumour may predict survival in NSCLC
Plasma ctDNA testing reduces time to treatment in advanced lung cancer
Is two years enough for immune checkpoint inhibitor therapy in non-small cell lung cancer?
Perioperative pembrolizumab improves event-free survival in early-stage lung cancer
